CENTAURI THERAPEUTICS LIMITED

LONDON

Unclaimed

Subcontracting experience

1 record from government sources. Past participation is not evidence of current teaming interest.

Role	Agency	Description	Vehicle	Obligated	Action date	Period
Subcontractor	Department of Health and Human Services	CENTAURI IS A PRIVATELY-OWNED BIOTECH COMPANY DEVELOPING NOVEL IMMUNOTHERAPEUTICS TO TREAT LIFE-THREATENING DISEASES. CENTAURI HAS A DEVELOPED AN IMMUNOTHERAPEUTIC PLATFORM (ALPHAMERS) THAT REDIRECTS PRE-EXISTING NATURAL ANTIBODIES TO TARGET SPECIFIC DISEASES WITH APPLICATIONS FOR CANCER AND INFECTIOUS DISEASE. ALPHAMERS ARE PART OF A LARGER FAMILY OF ANTIBODY RECRUITING MOLECULES (ARMS) DESIGNED TO REDIRECT A POTENT PRE-EXISTING IMMUNE RESPONSE AND THEREBY BRING ABOUT AN IMMEDIATE (WITHIN MINUTES) IMMUNOTHERAPEUTIC BENEFIT TO PATIENTS. THE ALPHAMER PLATFORM COMPRISES A TARGETING DOMAIN, THAT BINDS TO SPECIFICALLY TO THE BACTERIA, AN ANTIBODY-RECRUITING EFFECTOR DOMAIN THAT RECRUITS PRE-EXISTING NATURAL ANTI-GAL ANTIBODIES, AND PROPRIETARY LINKER TECHNOLOGY. ANTI-GAL ANTIBODIES ARE THE MOST ABUNDANT ANTIBODIES IN HUMANS, CONSTITUTING ABOUT 1% OF ALL IMMUNOGLOBULINS. THE ALPHAMER IS INTENDED TO RE-DIRECT THESE NATURALLY OCCURRING EFFECTOR ANTIBODIES WHICH ARE ALREADY PRESENT AT HIGH CONCENTRATIONS IN ALL PEOPLE TO TARGET BACTERIA FOR IMMUNE-MEDIATED DESTRUCTION, BY ACTIVATING THE COMPLEMENT CASCADE AND DESTROYING THE PATHOGEN THROUGH DIRECT LYSIS AND OPSONOPHAGOCYTOSIS. OUR LEAD PROGRAM (CTL-ABX01) TARGETS DRUG-SENSITIVE AND MULTI-DRUG RESISTANT (MDR) GRAM-NEGATIVE BACTERIA, INCLUDING CLINICALLY RELEVANT STRAINS OF ENTEROBACTERIACEAE, PSEUDOMONAS AERUGINOSA, AND ACINETOBACTER BAUMANNII. IN ADDITION TO RECRUITING THE IMMUNE SYSTEM, THE TARGETING DOMAIN OF THE ALPHAMER OF THE ABX01 PROGRAM HAS ALSO A DIRECT ANTIBACTERIAL EFFECT IN COMBINATION WITH ITS IMMUNOMODULATOR FUNCTION. AS SUCH, THE ALPHAMER SERVES AS A METHOD TO COMBINE THE POWER OF THE IMMUNE SYSTEM WITH DIRECT ANTIBACTERIAL ACTION IN ONE DRUG. THE AIM OF THIS PILOT PROJECT IS TO BETTER UNDERSTAND THE IMMUNE-MEDIATED TRANSLATION AND EFFICACY OF THE ALPHAMER IN VIVO BY EXECUTING APPROPRIATE DISEASE MODELS IN ORDER TO PREDICT AN EFFICACIOUS DOSE FOR HUMAN. PROJECT SUCCESS WOULD ENABLE US TO SELECT LEAD COMPOUNDS FOR CLINICAL CANDIDATE SELECTION STUDIES, COMPLETION OF PRE-IND-ENABLING STUDIES, AND CONDUCT OF A FIRST-IN-HUMAN STUDY. KC3386 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending	—	$1,805,406	Apr 17, 2025	— – —

Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.